Ethmoiditis-associated apex syndrome may result in temporary blindness after allo-SCT

被引：0
|
作者：
Olsson, R. [1 ]
Juto, J-E [2 ]
Mattsson, J. [1 ]
机构：
[1] Karolinska Univ Hosp, Karolinska Inst, Ctr Allogene Stem Cell Transplantat, Huddinge, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Otorhinolaryngol, Huddinge, Sweden
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 44卷 / 12期
关键词：
STEM-CELL TRANSPLANTATION; FUNGAL-INFECTIONS; RECIPIENTS; SINUSITIS;
D O I：
10.1038/bmt.2009.85
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：825 / 826
页数：2
相关论文
共 42 条
  • [21] Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT
    T Sauer
    G Silling
    C Groth
    F Rosenow
    U Krug
    D Görlich
    G Evers
    J Albring
    R Besoke
    R M Mesters
    C Müller-Tidow
    T Kessler
    T Büchner
    W E Berdel
    M Stelljes
    Bone Marrow Transplantation, 2015, 50 : 485 - 492
  • [22] High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT
    R Tizon
    N Frey
    D F Heitjan
    K S Tan
    S C Goldstein
    E O Hexner
    A Loren
    S M Luger
    R Reshef
    D Tsai
    D Vogl
    J Davis
    M Vozniak
    B Fuchs
    E A Stadtmauer
    D L Porter
    Bone Marrow Transplantation, 2012, 47 : 1332 - 1337
  • [23] Chest health surveillance utility in the early detection of bronchiolitis obliterans syndrome in children after allo-SCT
    Gassas, A.
    Craig-Barnes, H.
    Dell, S.
    Doyle, J.
    Schechter, T.
    Sung, L.
    Egeler, M.
    Palaniyar, N.
    BONE MARROW TRANSPLANTATION, 2013, 48 (06) : 814 - 818
  • [24] Erratum: Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions
    I A Hoevenaren
    L F D van Vulpen
    H Levenga
    M C Minnema
    R Raymakers
    Bone Marrow Transplantation, 2011, 46 : 322 - 322
  • [25] Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT
    Karl, F.
    Liang, C.
    Boettcher-Loschinski, R.
    Stoll, A.
    Flamann, C.
    Richter, S.
    Lischer, C.
    Voelkl, S.
    Jacobs, B.
    Boettcher, M.
    Jitschin, R.
    Bruns, H.
    Fischer, T.
    Holler, E.
    Roesler, W.
    Dandekar, T.
    Mackensen, A.
    Mougiakakos, D.
    BLOOD, 2023, 141 (13) : 1626 - 1639
  • [26] Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions (vol 46, pg 319, 2011)
    Hoevenaren, I. A.
    van Vulpen, L. F. D.
    Levenga, H.
    Minnema, M. C.
    Raymakers, R.
    BONE MARROW TRANSPLANTATION, 2011, 46 (02) : 322 - 322
  • [27] 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
    Czibere, A.
    Bruns, I.
    Kroeger, N.
    Platzbecker, U.
    Lind, J.
    Zohren, F.
    Fenk, R.
    Germing, U.
    Schroeder, T.
    Graef, T.
    Haas, R.
    Kobbe, G.
    BONE MARROW TRANSPLANTATION, 2010, 45 (05) : 872 - 876
  • [28] 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
    A Czibere
    I Bruns
    N Kröger
    U Platzbecker
    J Lind
    F Zohren
    R Fenk
    U Germing
    T Schröder
    T Gräf
    R Haas
    G Kobbe
    Bone Marrow Transplantation, 2010, 45 : 872 - 876
  • [29] GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT
    Parody, R.
    Lopez-Corral, L.
    Godino, O. L.
    Cadenas, I. G.
    Martinez, A. P.
    Vazquez, L.
    Martino, R.
    Martinez, C.
    Solano, C.
    Barba, P.
    Valcarcel, D.
    Caballero-Velazquez, T.
    Marquez-Malaver, F. J.
    Sierra, J.
    Caballero, D.
    Perez-Simon, J. A.
    BONE MARROW TRANSPLANTATION, 2015, 50 (01) : 121 - 126
  • [30] GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT
    R Parody
    L Lopez-Corral
    O L Godino
    I G Cadenas
    A P Martinez
    L Vazquez
    R Martino
    C Martinez
    C Solano
    P Barba
    D Valcarcel
    T Caballero-Velazquez
    F J Marquez-Malaver
    J Sierra
    D Caballero
    J A Perez-Simón
    Bone Marrow Transplantation, 2015, 50 : 121 - 126
12345